Email lin_liang@moh.gov.sg

“Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle. The purpose is to inform decision making in order to promote an equitable, efficient, and high-quality health system.”

Ms Lin Liang and her team conduct HTA and publish technology guidances on theclinical– and cost-effectiveness of health technologies. To make healthcare more accessible, the team engages manufacturers in value-based pricing negotiations to ensure prices are commensurate with the outcomes they deliver for patients and the Singapore health system.

• NUS Saw Swee Hock School of Public Health (Adjunct)
• Head (HTA), Agency for Care Effectiveness, Ministry of Health (Primary)

• Health Technology Assessment
• Health Economics & Outcomes Research
• Health Systems and Policies
• Pricing and Reimbursement of Pharmaceuticals & Medical Technologies

• Master of Science, International health technology assessment, pricing and reimbursement
• Bachelor of Science (Pharmacy) First Class Honours

• Head (HTA), Agency for Care Effectiveness (2016 – Present)
• Principal Research Analyst, Health Technology Assessment, National Healthcare Group (2012 – 2016)
• Medical Science Liaison, Medical Affairs, Merck Sharp Dohme (2010 to 2012)
• Project Manager, Market Research, Synovate Healthcare (2007 to 2010)

• Lin L, Zhao YJ, Chew PT, Sng CC, Wong HT, Yip LW, Wu TS, Bautista D, Teng M, Khoo AL, Lim BP. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014 Dec;48(12):1585-93. doi: 10.1177/1060028014548569. Epub 2014 Sep 2. PMID: 25184309.
• Lin L, Teng M, Zhao YJ, Khoo AL, Seet RC, Yong QW, Yeo TC, Lim BP. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly. Cardiovasc Drugs Ther. 2015 Apr;29(2):187-97. doi: 10.1007/s10557-015-6584-7. PMID: 25860556.
• Lin L, Lim WS, Zhou HJ, Khoo AL, Tan KT, Chew AP, Foo D, Chin JJ, Lim BP. Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis. J Am Med Dir Assoc. 2015 Dec;16(12):1103.e1-19. doi: 10.1016/j.jamda.2015.09.008. Epub 2015 Oct 31. PMID: 26527225.
• Zhao YJ, Khoo AL, Lin L, Teng M, Wu TS, Chan MY, Lim BP. Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome. Value Health Reg Issues. 2016 May;9:22-27. doi: 10.1016/j.vhri.2015.07.001. Epub 2015 Oct 1. PMID: 27881255.
• Teng M, Khoo AL, Zhao YJ, Lin L, Lim BP. Integrating Health Technology Assessment Principles into Formulary Management. Int J Technol Assess Health Care. 2016 Jan;32(1-2):81-7. doi: 10.1017/S0266462316000040. Epub 2016 Mar 22. PMID: 27001376.
• Lin L, Zhao YJ, Zhou HJ, Khoo AL, Teng M, Soh LB, Lim BP, Sim K. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. Int Clin Psychopharmacol. 2016 Mar;31(2):84-92. doi: 10.1097/YIC.0000000000000111. PMID: 26619182.
• Zhao YJ, Khoo AL, Lin L, Teng M, Koh CJ, Lim SG, Lim BP, Dan YY. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. J Gastroenterol Hepatol. 2016 Sep;31(9):1628-37. doi: 10.1111/jgh.13341. PMID: 26990023.
• Liang L, Bin-Chia Wu D, Aziz MIA, Wong R, Sim D, Leong KTG, Wei YQ, Tan D, Ng K. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. J Med Econ. 2018 Feb;21(2):174-181. doi: 10.1080/13696998.2017.1387119. Epub 2017 Oct 10. PMID: 28959905.
• Aziz MIA, Tan LE, Wu DB, Pearce F, Chua GSW, Lin L, Tan PT, Ng K. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018 Oct 9;13:3203-3231. doi: 10.2147/COPD.S173472. PMID: 30349228; PMCID: PMC6186767.
• Pearce F, Lin L, Teo E, Ng K, Khoo D. Health Technology Assessment and Its Use in Drug Policies: Singapore. Value Health Reg Issues. 2019 May;18:176-183. doi: 10.1016/j.vhri.2018.03.007. Epub 2018 Jun 25. PMID: 29954696.
• Teng M, Zhou HJ, Lin L, Lim PH, Yeo D, Goh S, Tjan SY, Lim BP. Cost-effectiveness of hydrotherapy versus land-based therapy in patients with musculoskeletal disorders in Singapore. J Public Health (Oxf). 2019 Jun 1;41(2):391-398. doi: 10.1093/pubmed/fdy044. PMID: 29534234.
• Wong WQ, Lin L, Ju H, Ng K. Towards greater impact in health technology assessment: horizon scanning for new and emerging technologies in Singapore. Int J Technol Assess Health Care. 2020 Jun 22:1-7. doi: 10.1017/S0266462320000343. Epub ahead of print. PMID: 32624047.
• Cher BP, Gan KY, Aziz MIA, Lin L, Hwang WYK, Poon LM, Ng K. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective. J Med Econ. 2020 Nov;23(11):1321-1329. doi: 10.1080/13696998.2020.1808981. Epub 2020 Aug 25. PMID: 32780608.
• Tan CK, Luo XS, Ong BS, Lin L, Ng KH. Real-world impact of a subsidy decision of sofosbuvir-velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes. JGH Open. 2022 Nov 29;7(1):48-54. doi: 10.1002/jgh3.12850. PMID: 36660045; PMCID: PMC9840192.           

• Tan SH, Goh LGH, Ong BS, Ng SG, Lin L, Ng CH Thong YH, Ng K. Impact of Value-Driven Healthcare Strategies to Optimise Biosimilar Use: The Singapore Story. Applied Health Economics and Health Policy. 2024.